The survival of stage III gastric cancer patients is affected by the number of lymph nodes removed

BACKGROUND: Lymph node (LN) removal has been an important component in surgical treatment of gastric cancer. However, it is not clear whether the number of lymph nodes resected affects patient survival. METHODS: We retrospectively reviewed the records of 147 patients with adenocarcinoma of the stomach who had undergone gastrectomy with curative intent between 1992 and 2001. Patients were divided into two groups: group I patients had < or =15 (n=124) and group II patients had >15 (n=23) LN reported. RESULTS: The two groups were similar in age, gender distribution, and tumor locations. Group II patients had more advanced tumor, node, and overall staging. The median survival was 23.0 and 31.8 months for groups I and II, respectively. In stage III patients, median survival was 14.4 months for group I and 33.8 months for group II (P=.006). Group II patients also had more proximal lesions (P<.001) and a decreased positive to removed LN ratio (P=.014). CONCLUSION: For stage III disease, removal of >15 LN appears to contribute to a considerable survival advantage. Because extended lymphadenectomy will most reliably allow >15 LN removed and add no operative morbidity and mortality, we strongly recommend it be considered in curative resections of gastric cancer.